Erratum: Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial
Unknown authors
Abstract
46 (34-58) 56 (49-64) 28 (21-35) 41 (29-54) 10 (4-20) 53 (46-59) 23 (18-29
Topics & Concepts
MedicineCabozantinibSunitinibNivolumabRenal cell carcinomaInternal medicineOncologyUrologyCancerImmunotherapyRenal cell carcinoma treatment